The US Food and Drug Administration has approved the use of tecentriq or atezolizumab from the Swiss pharmaceutical company (Roche) as an adjunctive treatment, after surgery and chemotherapy with platinum, in adults with non-small-cell lung cancer (NSCLC) stage II and II. Determined by an Food and Drug Administration-approved test, the company said in a statement.
The results showed that treatment with Tecentriq, after surgery and platinum-based chemotherapy, reduced the risk of disease recurrence or death by 34% in people with stage 2 and stage 2 lung cancer, compared to the best supportive care.
These were the details of the news FDA approves new drug for lung cancer for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at saudi24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
